{"id": "article-18367_0", "title": "Bleeding Disorders -- Continuing Education Activity", "content": "Hereditary bleeding disorders occur due to the absence or deficiency of specific clotting proteins. The three most common hereditary bleeding disorders are hemophilia A (factor VIII deficiency), hemophilia B (factor IX deficiency) and von Willebrand disease. This activity reviews the evaluation and management of hereditary bleeding disorders and highlights the role of the interprofessional team in caring for affected patients.", "contents": "Bleeding Disorders -- Continuing Education Activity. Hereditary bleeding disorders occur due to the absence or deficiency of specific clotting proteins. The three most common hereditary bleeding disorders are hemophilia A (factor VIII deficiency), hemophilia B (factor IX deficiency) and von Willebrand disease. This activity reviews the evaluation and management of hereditary bleeding disorders and highlights the role of the interprofessional team in caring for affected patients."}
{"id": "article-18367_1", "title": "Bleeding Disorders -- Continuing Education Activity", "content": "Objectives: Describe the presentation of hereditary bleeding disorders. Describe the evaluation of hereditary bleeding disorders. Review the treatment options for hereditary bleeding disorders. Explain the importance of improving care coordination amongst the interprofessional team to enhance the management of patients with hereditary bleeding disorders. Access free multiple choice questions on this topic.", "contents": "Bleeding Disorders -- Continuing Education Activity. Objectives: Describe the presentation of hereditary bleeding disorders. Describe the evaluation of hereditary bleeding disorders. Review the treatment options for hereditary bleeding disorders. Explain the importance of improving care coordination amongst the interprofessional team to enhance the management of patients with hereditary bleeding disorders. Access free multiple choice questions on this topic."}
{"id": "article-18367_2", "title": "Bleeding Disorders -- Introduction", "content": "The body possesses innate mechanisms to control bleeding in the setting of an injury. \u00a0 An understanding of these basic physiologic processes is critical to aid in the identification and diagnosis of bleeding disorders.\u00a0 The hemostatic system is responsible for maintaining blood in a fluid state, free of the aggregation of platelets and thrombus formation with the help of prostacyclin, antithrombin III and nitric oxide within the endothelial cells.\u00a0 These naturally occurring substances found in the blood assist in the prevention of clots by causing conversion of plasminogen to plasmin to promote fibrinolysis. \u00a0\u00a0Damage or injury to the endothelium will initiate a cascade of events in an attempt to control bleeding.\u00a0 Disruption of the endothelium will first cause local vasoconstriction to occur, limiting blood flow to the area. Primary hemostasis initiates by platelets with the release of von Willebrand factor (vWF), a large plasma glycoprotein made and stored in endothelial cells and megakaryocytes. \u00a0Platelets and vWF will combine to form a plug at the site of injury.\u00a0 Circulating vWF continues to bind with collagen and Factor VIII as well as other endothelial substances, allowing the platelet plug to adhere to the area of injury. [1] Through activation of the clotting cascade (see image) and secondary hemostasis, this initial platelet plug will get reinforced to a sturdy fibrin clot. \u00a0The clotting cascade operates through a dual process system in which the various\u00a0clotting factors become activated\u00a0with the result being the formation of a fibrin strand or clot at the site of tissue injury. \u00a0A\u00a0deficiency of any of the essential clotting factors will result in difficulty forming a fibrin clot, and excessive bleeding can\u00a0occur.", "contents": "Bleeding Disorders -- Introduction. The body possesses innate mechanisms to control bleeding in the setting of an injury. \u00a0 An understanding of these basic physiologic processes is critical to aid in the identification and diagnosis of bleeding disorders.\u00a0 The hemostatic system is responsible for maintaining blood in a fluid state, free of the aggregation of platelets and thrombus formation with the help of prostacyclin, antithrombin III and nitric oxide within the endothelial cells.\u00a0 These naturally occurring substances found in the blood assist in the prevention of clots by causing conversion of plasminogen to plasmin to promote fibrinolysis. \u00a0\u00a0Damage or injury to the endothelium will initiate a cascade of events in an attempt to control bleeding.\u00a0 Disruption of the endothelium will first cause local vasoconstriction to occur, limiting blood flow to the area. Primary hemostasis initiates by platelets with the release of von Willebrand factor (vWF), a large plasma glycoprotein made and stored in endothelial cells and megakaryocytes. \u00a0Platelets and vWF will combine to form a plug at the site of injury.\u00a0 Circulating vWF continues to bind with collagen and Factor VIII as well as other endothelial substances, allowing the platelet plug to adhere to the area of injury. [1] Through activation of the clotting cascade (see image) and secondary hemostasis, this initial platelet plug will get reinforced to a sturdy fibrin clot. \u00a0The clotting cascade operates through a dual process system in which the various\u00a0clotting factors become activated\u00a0with the result being the formation of a fibrin strand or clot at the site of tissue injury. \u00a0A\u00a0deficiency of any of the essential clotting factors will result in difficulty forming a fibrin clot, and excessive bleeding can\u00a0occur."}
{"id": "article-18367_3", "title": "Bleeding Disorders -- Introduction", "content": "Bleeding disorders fall into two main categories: inherited and acquired.\u00a0 Inherited bleeding disorders have a genetic predisposition and involve a deficiency of coagulation factors. Acquired bleeding disorders can be caused by conditions that an individual may develop at any point during their lifetime.\u00a0 These can be broader in range and dependent on comorbid conditions. \u00a0The focus of this discussion will be on congenital coagulopathies; acquired bleeding disorders will be considered to be outside the scope of the information presented here.", "contents": "Bleeding Disorders -- Introduction. Bleeding disorders fall into two main categories: inherited and acquired.\u00a0 Inherited bleeding disorders have a genetic predisposition and involve a deficiency of coagulation factors. Acquired bleeding disorders can be caused by conditions that an individual may develop at any point during their lifetime.\u00a0 These can be broader in range and dependent on comorbid conditions. \u00a0The focus of this discussion will be on congenital coagulopathies; acquired bleeding disorders will be considered to be outside the scope of the information presented here."}
{"id": "article-18367_4", "title": "Bleeding Disorders -- Etiology", "content": "Hemophilia, an x-linked heredity disorder, is diagnosed by an abnormal concentration of Factor VIII or IX.\u00a0 Approximately one-third of cases arise from a spontaneous mutation.\u00a0\u00a0 Von Willebrand disease, with an autosomal dominant inheritance pattern, has variable penetrance and clinical symptoms can vary from person to person.\u00a0 The most severe pathology occurs in homozygotes. [2] Neither bleeding disorder has a predilection for a specific race.", "contents": "Bleeding Disorders -- Etiology. Hemophilia, an x-linked heredity disorder, is diagnosed by an abnormal concentration of Factor VIII or IX.\u00a0 Approximately one-third of cases arise from a spontaneous mutation.\u00a0\u00a0 Von Willebrand disease, with an autosomal dominant inheritance pattern, has variable penetrance and clinical symptoms can vary from person to person.\u00a0 The most severe pathology occurs in homozygotes. [2] Neither bleeding disorder has a predilection for a specific race."}
{"id": "article-18367_5", "title": "Bleeding Disorders -- Epidemiology", "content": "Hereditary bleeding disorders are due to the absence or deficiency of specific clotting proteins which act as procoagulants through precise interactions in the clotting cascade.\u00a0 The three most common are hemophilia A (Factor VIII deficiency), hemophilia B (Factor IX deficiency) and von Willebrand disease.\u00a0\u00a0 Hemophilia A is an X-linked recessive genetic disorder affecting 1 in 5000 males making it the most common congenital coagulopathy.\u00a0 Hemophilia B is an X-linked genetic coagulopathy affecting 1 in 30000 male births. \u00a0Hemophilia B is also known as Christmas disease. The origin of its namesake is from Steven Christmas, the first patient diagnosed with Hemophilia B in 1952. \u00a0Since hemophilia is genetic, its prevalence increases in populations in which higher levels of consanguinity exists.\u00a0 Females may be asymptomatic carriers of the hemophilia gene or may be found to have a partial deficiency of the specific factors involved. Von Willebrand disease is an autosomal dominant trait with no predilection for sex; however, women are more likely to exhibit symptoms as a result of increased bleeding during menstruation. [3] Von Willebrand disease was first described in 1926 by Finnish physician Erik Adolf von Willebrand. According to the CDC, von Willebrand disease affects approximately 1% of the general population. [4]", "contents": "Bleeding Disorders -- Epidemiology. Hereditary bleeding disorders are due to the absence or deficiency of specific clotting proteins which act as procoagulants through precise interactions in the clotting cascade.\u00a0 The three most common are hemophilia A (Factor VIII deficiency), hemophilia B (Factor IX deficiency) and von Willebrand disease.\u00a0\u00a0 Hemophilia A is an X-linked recessive genetic disorder affecting 1 in 5000 males making it the most common congenital coagulopathy.\u00a0 Hemophilia B is an X-linked genetic coagulopathy affecting 1 in 30000 male births. \u00a0Hemophilia B is also known as Christmas disease. The origin of its namesake is from Steven Christmas, the first patient diagnosed with Hemophilia B in 1952. \u00a0Since hemophilia is genetic, its prevalence increases in populations in which higher levels of consanguinity exists.\u00a0 Females may be asymptomatic carriers of the hemophilia gene or may be found to have a partial deficiency of the specific factors involved. Von Willebrand disease is an autosomal dominant trait with no predilection for sex; however, women are more likely to exhibit symptoms as a result of increased bleeding during menstruation. [3] Von Willebrand disease was first described in 1926 by Finnish physician Erik Adolf von Willebrand. According to the CDC, von Willebrand disease affects approximately 1% of the general population. [4]"}
{"id": "article-18367_6", "title": "Bleeding Disorders -- Pathophysiology", "content": "Bleeding disorders may present in correlation with their severity, and some may be undetected until a major trauma or surgery occur. \u00a0Patients with a severe form of hemophilia In hemophilia, \u00a0categorized as less than 1% of normal plasma levels, will often present with 20 to 30 episodes of epistaxis a year, excessive bleeding after minor traumas or\u00a0into muscles and joints (hemarthrosis).\u00a0 Diagnosis usually occurs within the first two years of life and can be immediately evident after circumcision.\u00a0\u00a0 Newborns can also present with intracranial hemorrhages, cephalohematoma or umbilical cord bleeding immediately following delivery. [5] Those with a more moderate form of the disease (6 to 30% of normal levels) may only bleed excessively after surgery or a major trauma.", "contents": "Bleeding Disorders -- Pathophysiology. Bleeding disorders may present in correlation with their severity, and some may be undetected until a major trauma or surgery occur. \u00a0Patients with a severe form of hemophilia In hemophilia, \u00a0categorized as less than 1% of normal plasma levels, will often present with 20 to 30 episodes of epistaxis a year, excessive bleeding after minor traumas or\u00a0into muscles and joints (hemarthrosis).\u00a0 Diagnosis usually occurs within the first two years of life and can be immediately evident after circumcision.\u00a0\u00a0 Newborns can also present with intracranial hemorrhages, cephalohematoma or umbilical cord bleeding immediately following delivery. [5] Those with a more moderate form of the disease (6 to 30% of normal levels) may only bleed excessively after surgery or a major trauma."}
{"id": "article-18367_7", "title": "Bleeding Disorders -- Pathophysiology", "content": "Von Willebrand factor (vWF) is a glycoprotein produced in endothelial cells and megakaryocytes that is responsible for facilitating platelet binding after injury of the endothelial surface occurs. Von Willebrand disease is a common congenital bleeding disorder in which there is a deficiency or dysfunction of vWF. \u00a0Factor VIII levels can be affected as well.\u00a0 The disease presents similarly to that of a platelet abnormality and can exhibit variable clinical symptomatology from mild mucocutaneous bleeding of the nose or gingiva or menorrhagia to hemarthrosis in more severe cases. The disease categorized into three types.\u00a0 Type I is the most common, representing 60 to 80% of cases. \u00a0Type 1 von Willebrand disease is a heterozygous deficiency in which there may be only 20% to 40% of normal levels of vWF in addition to a reduction in Factor VIII levels.\u00a0 Patients with Type I von Willebrand disease can present with mild clinical symptoms like a propensity for easy bruising, mucosal bleeding or menorrhagia. [6] Medications which\u00a0inhibit\u00a0prostaglandin and thromboxane synthesis may significantly exacerbate symptoms and can often aid in initial diagnosis. [7] Type 2 von Willebrand disease is less common, representing approximately 17% of the reported cases, and is characterized by a qualitatively abnormal vWF which can also be associated with thrombocytopenia and decreased Factor VIII. \u00a0There are four distinct\u00a0subtypes within the Type 2 category. \u00a0Type 2A lacks a normal vWF multimer because of abnormal proteolysis or reduced secretion of the factor. \u00a0Type 2B is a mutation which causes the vWF to be hyperactive and have an increased binding affinity to platelets causing the creation of complexes which are quickly cleared from the circulation, ultimately resulting in thrombocytopenia. [8] Type 2M possesses a decreased platelet binding ability to vWF with depleted factor levels, and Type 2N exhibits a decrease in binding of vWF to Factor VIII. \u00a0Type 3 is the rarest and the most severe form of the disease representing approximately 3% of the cases, where there are markedly diminished levels of vWF and FVIII.", "contents": "Bleeding Disorders -- Pathophysiology. Von Willebrand factor (vWF) is a glycoprotein produced in endothelial cells and megakaryocytes that is responsible for facilitating platelet binding after injury of the endothelial surface occurs. Von Willebrand disease is a common congenital bleeding disorder in which there is a deficiency or dysfunction of vWF. \u00a0Factor VIII levels can be affected as well.\u00a0 The disease presents similarly to that of a platelet abnormality and can exhibit variable clinical symptomatology from mild mucocutaneous bleeding of the nose or gingiva or menorrhagia to hemarthrosis in more severe cases. The disease categorized into three types.\u00a0 Type I is the most common, representing 60 to 80% of cases. \u00a0Type 1 von Willebrand disease is a heterozygous deficiency in which there may be only 20% to 40% of normal levels of vWF in addition to a reduction in Factor VIII levels.\u00a0 Patients with Type I von Willebrand disease can present with mild clinical symptoms like a propensity for easy bruising, mucosal bleeding or menorrhagia. [6] Medications which\u00a0inhibit\u00a0prostaglandin and thromboxane synthesis may significantly exacerbate symptoms and can often aid in initial diagnosis. [7] Type 2 von Willebrand disease is less common, representing approximately 17% of the reported cases, and is characterized by a qualitatively abnormal vWF which can also be associated with thrombocytopenia and decreased Factor VIII. \u00a0There are four distinct\u00a0subtypes within the Type 2 category. \u00a0Type 2A lacks a normal vWF multimer because of abnormal proteolysis or reduced secretion of the factor. \u00a0Type 2B is a mutation which causes the vWF to be hyperactive and have an increased binding affinity to platelets causing the creation of complexes which are quickly cleared from the circulation, ultimately resulting in thrombocytopenia. [8] Type 2M possesses a decreased platelet binding ability to vWF with depleted factor levels, and Type 2N exhibits a decrease in binding of vWF to Factor VIII. \u00a0Type 3 is the rarest and the most severe form of the disease representing approximately 3% of the cases, where there are markedly diminished levels of vWF and FVIII."}
{"id": "article-18367_8", "title": "Bleeding Disorders -- History and Physical -- Hemophilia:", "content": "While mild hemophilia may only present after a traumatic injury or surgery, those with a moderate to severe form of the disease may exhibit hallmark characteristics such as mucosal or gingival bleeding, easy bruising, and hematoma formation.\u00a0 The concern is when there is bleeding into joints, particularly in the ankles, knees, and elbows, referred to as hemarthrosis.\u00a0 Hemarthrosis can initiate an inflammatory process to occur in which the joints become painfully swollen and eventually limit motion. [9] There is potential for the perpetuation of a vicious cycle whereby the joints are damaged resulting in synovitis, and an area for subsequent bleeding can occur.\u00a0 Over time hemophilic arthropathy occurs with joint narrowing, bone cysts and a decreased range of motion.\u00a0 Bleeding into muscle\u00a0tissue\u00a0from minor traumas can result in anemia and compression of vital structures and nerves leading to compartment syndrome.\u00a0 Bleeding less frequently occurs in the urinary and gastrointestinal tracts.\u00a0 These patients are at significant risk of intracranial bleeds which would be a life-threatening emergency.\u00a0 Hemophilia can present in infancy with cephalohematoma formation after vaginal birth and with significant bleeding after circumcisions.", "contents": "Bleeding Disorders -- History and Physical -- Hemophilia:. While mild hemophilia may only present after a traumatic injury or surgery, those with a moderate to severe form of the disease may exhibit hallmark characteristics such as mucosal or gingival bleeding, easy bruising, and hematoma formation.\u00a0 The concern is when there is bleeding into joints, particularly in the ankles, knees, and elbows, referred to as hemarthrosis.\u00a0 Hemarthrosis can initiate an inflammatory process to occur in which the joints become painfully swollen and eventually limit motion. [9] There is potential for the perpetuation of a vicious cycle whereby the joints are damaged resulting in synovitis, and an area for subsequent bleeding can occur.\u00a0 Over time hemophilic arthropathy occurs with joint narrowing, bone cysts and a decreased range of motion.\u00a0 Bleeding into muscle\u00a0tissue\u00a0from minor traumas can result in anemia and compression of vital structures and nerves leading to compartment syndrome.\u00a0 Bleeding less frequently occurs in the urinary and gastrointestinal tracts.\u00a0 These patients are at significant risk of intracranial bleeds which would be a life-threatening emergency.\u00a0 Hemophilia can present in infancy with cephalohematoma formation after vaginal birth and with significant bleeding after circumcisions."}
{"id": "article-18367_9", "title": "Bleeding Disorders -- History and Physical -- Von Willebrand Disease", "content": "Von Willebrand disease can exhibit clinical signs and symptoms starting in childhood with a history of easy bruising and bleeding.\u00a0 While patients with a very mild version of the disease may not have clinical symptoms at all, patients with vWF that is qualitative or quantitatively low may present with a predisposition to mucosal bleeding and episodic epistaxis.\u00a0 Women with von Willebrand disease may have significant menorrhagia which is often a presenting sign of the illness, precipitating a workup and eventual diagnosis. [10] These patients can also go unrecognized until undergoing major surgery or experiencing a traumatic injury.", "contents": "Bleeding Disorders -- History and Physical -- Von Willebrand Disease. Von Willebrand disease can exhibit clinical signs and symptoms starting in childhood with a history of easy bruising and bleeding.\u00a0 While patients with a very mild version of the disease may not have clinical symptoms at all, patients with vWF that is qualitative or quantitatively low may present with a predisposition to mucosal bleeding and episodic epistaxis.\u00a0 Women with von Willebrand disease may have significant menorrhagia which is often a presenting sign of the illness, precipitating a workup and eventual diagnosis. [10] These patients can also go unrecognized until undergoing major surgery or experiencing a traumatic injury."}
{"id": "article-18367_10", "title": "Bleeding Disorders -- Evaluation -- Laboratory Evaluation for Bleeding Disorders", "content": "Laboratory testing is essential for diagnosing bleeding disorders. However, the specific panels necessary for an accurate diagnostic evaluation are not standardized and may vary significantly between hospitals and regions. \u00a0Routine laboratory analysis for clotting disorders starts with platelet count, prothrombin time (PT), partial thromboplastin time (aPTT), the international normalized ratio (INR) and bleeding time. The platelet count should not only have a sufficient quantity (normal = 150000 to 500000/ml) but must also be functional.\u00a0The bleeding time assesses the function of the platelets. Bleeding times can be delayed in a patient with vWF deficiency or from specific medications that interfere with platelet function (NSAIDS, aspirin and valproic acid). \u00a0\u00a0PT (normal = 11.5 to 14s) represents the function of coagulation factors II, V, VII, and X which are the hepatically synthesized vitamin K dependent factors.\u00a0 The PT and INR will be affected by patients taking warfarin as it interferes with the synthesis of vitamin K dependent factors. The INR (normal= 0.8 to 1.2) is a ratio that is used to estimate the percent of functional clotting factors.\u00a0 For example, an INR of between 2 to 3 correlates approximately to 10% of active clotting factors present.\u00a0 It is necessary to have at least 30% of the clotting factors present for normal coagulation. \u00a0Partial thromboplastin time (normal = 25 to 40s) measures the efficacy of von Willebrand Factor and factors VIII, IX, XI, and XII. [11]", "contents": "Bleeding Disorders -- Evaluation -- Laboratory Evaluation for Bleeding Disorders. Laboratory testing is essential for diagnosing bleeding disorders. However, the specific panels necessary for an accurate diagnostic evaluation are not standardized and may vary significantly between hospitals and regions. \u00a0Routine laboratory analysis for clotting disorders starts with platelet count, prothrombin time (PT), partial thromboplastin time (aPTT), the international normalized ratio (INR) and bleeding time. The platelet count should not only have a sufficient quantity (normal = 150000 to 500000/ml) but must also be functional.\u00a0The bleeding time assesses the function of the platelets. Bleeding times can be delayed in a patient with vWF deficiency or from specific medications that interfere with platelet function (NSAIDS, aspirin and valproic acid). \u00a0\u00a0PT (normal = 11.5 to 14s) represents the function of coagulation factors II, V, VII, and X which are the hepatically synthesized vitamin K dependent factors.\u00a0 The PT and INR will be affected by patients taking warfarin as it interferes with the synthesis of vitamin K dependent factors. The INR (normal= 0.8 to 1.2) is a ratio that is used to estimate the percent of functional clotting factors.\u00a0 For example, an INR of between 2 to 3 correlates approximately to 10% of active clotting factors present.\u00a0 It is necessary to have at least 30% of the clotting factors present for normal coagulation. \u00a0Partial thromboplastin time (normal = 25 to 40s) measures the efficacy of von Willebrand Factor and factors VIII, IX, XI, and XII. [11]"}
{"id": "article-18367_11", "title": "Bleeding Disorders -- Evaluation -- Laboratory Evaluation for Bleeding Disorders", "content": "Hemophiliacs will have an elevated aPTT and a normal PT/INR, bleeding time and platelet count.\u00a0 The aPTT, a measure of the intrinsic pathway, will be elevated as a result of low levels of FVIII.\u00a0 An elevated aPTT should prompt investigation by looking at individual factor levels, specifically Factor VIII and IX. [12] When evaluating specific factor levels, the amount of factor present will determine the severity of the disease.\u00a0When the diagnosis is suspected, emphasis must also focus on family history including maternal male family members.", "contents": "Bleeding Disorders -- Evaluation -- Laboratory Evaluation for Bleeding Disorders. Hemophiliacs will have an elevated aPTT and a normal PT/INR, bleeding time and platelet count.\u00a0 The aPTT, a measure of the intrinsic pathway, will be elevated as a result of low levels of FVIII.\u00a0 An elevated aPTT should prompt investigation by looking at individual factor levels, specifically Factor VIII and IX. [12] When evaluating specific factor levels, the amount of factor present will determine the severity of the disease.\u00a0When the diagnosis is suspected, emphasis must also focus on family history including maternal male family members."}
{"id": "article-18367_12", "title": "Bleeding Disorders -- Evaluation -- Laboratory Evaluation for Bleeding Disorders", "content": "Diagnosis of von Willebrand disease is represented by increased bleeding time and a decrease in vWF levels as measured by the ristocetin cofactor collagen\u00a0binding, in addition to a history of bleeding and positive family history of von Willebrand disease.\u00a0 The reocmmendation is that patients are tested at least three times before making the official diagnosis as vWF levels are subject to fluctuate, changing with stress, pregnancy, exercise, and inflammatory processes. \u00a0\u00a0There are also some subtle differences in vWF levels based on gender and blood type. [13] Von Willebrand disease requires factor multimer assays to diagnose the specific subtype of the disease. \u00a0Additionally, the aPTT may be mildly elevated in approximately 50% of patients with von Willebrand disease second to low levels of factor VIII.", "contents": "Bleeding Disorders -- Evaluation -- Laboratory Evaluation for Bleeding Disorders. Diagnosis of von Willebrand disease is represented by increased bleeding time and a decrease in vWF levels as measured by the ristocetin cofactor collagen\u00a0binding, in addition to a history of bleeding and positive family history of von Willebrand disease.\u00a0 The reocmmendation is that patients are tested at least three times before making the official diagnosis as vWF levels are subject to fluctuate, changing with stress, pregnancy, exercise, and inflammatory processes. \u00a0\u00a0There are also some subtle differences in vWF levels based on gender and blood type. [13] Von Willebrand disease requires factor multimer assays to diagnose the specific subtype of the disease. \u00a0Additionally, the aPTT may be mildly elevated in approximately 50% of patients with von Willebrand disease second to low levels of factor VIII."}
{"id": "article-18367_13", "title": "Bleeding Disorders -- Treatment / Management", "content": "The mainstay treatment of hemophilia is factor replacement, either prophylactically or need-based.\u00a0 Recombinant-derived Factor VIII and IX concentrates are available and prevent the risk of viral transmission. [14] Recombinant Factor VIII increases the plasma concentration by 2% for every 1 IU/kg, and recombinant factor IX produces an increase of 0.8% for every 1IU/kg given.\u00a0 The goals of correction are to achieve a 50% plasma value for the management of\u00a0bleeding risks such as surgery and 100% correction in the setting of major trauma. \u00a0\u00a0These levels should be obtained 30 minutes before the onset of surgery and maintained for 2 to 7 days after surgery.\u00a0 The timing of subsequent doses is determined based on factor half-life which is typically 8 to 12 hours.", "contents": "Bleeding Disorders -- Treatment / Management. The mainstay treatment of hemophilia is factor replacement, either prophylactically or need-based.\u00a0 Recombinant-derived Factor VIII and IX concentrates are available and prevent the risk of viral transmission. [14] Recombinant Factor VIII increases the plasma concentration by 2% for every 1 IU/kg, and recombinant factor IX produces an increase of 0.8% for every 1IU/kg given.\u00a0 The goals of correction are to achieve a 50% plasma value for the management of\u00a0bleeding risks such as surgery and 100% correction in the setting of major trauma. \u00a0\u00a0These levels should be obtained 30 minutes before the onset of surgery and maintained for 2 to 7 days after surgery.\u00a0 The timing of subsequent doses is determined based on factor half-life which is typically 8 to 12 hours."}
{"id": "article-18367_14", "title": "Bleeding Disorders -- Treatment / Management", "content": "The treatment of von Willebrand disease consists of desmopressin (DDAVP) or cryoprecipitate.\u00a0 DDAVP will enhance the release of vWF in patients with Type 1 von Willebrand disease. \u00a0DDAVP is a synthetic derivative of antidiuretic hormone that acts on type 2 vasopressin receptors.\u00a0 It works by stimulating the release of vWF from endothelial cells by way of signaling through the cyclic adenosine monophosphate pathway which prompts the release of Weibel-Palade bodies into the endothelial cells and eventually into the plasma. [15] Additionally, DDAVP works on the renal collecting duct as an anti-diuretic.\u00a0 It reduces the amount of water that is eliminated in the urine potentially causing dilutional hyponatremia; therefore, patients should have fluid restriction maintained while receiving this medication. [16] DDAVP administered intravenously (0.3mcg/kg) will increase plasma Factor VIII and VWF levels by 3 to 5 times their baseline within 30 to 60 minutes after administration.\u00a0 DDAVP can also be administered subcutaneously (0.3 mcg/kg) or at fixed intranasal doses which is convenient for prophylactic treatment at home.\u00a0 DDAVP administration is expected to raise levels to 30 to 50% in patients with a baseline of 10% factor activity which may be sufficient for low-risk procedures but may require further supplementation to increase vWF to adequate levels needed for trauma or major surgery.\u00a0 Patients with a baseline of 20% factor level receiving DDAVP can see levels rise to 60 to 100% which would be suitable for most surgical procedures.\u00a0Approximately 10% of patients within the Type 1 category may fail to respond to DDAVP; therefore, the recommendation is that patients undergo a trial of DDAVP administration at diagnosis or before its clinical need.\u00a0 Patients with Type 2 and 3 von Willebrand disease typically require replacement products consisting of Factor VIII and vWF. It is also important to note that patients with Type 2a and 3 will not respond to DDAVP as the former possesses dysfunctional vWF and Type 3 lacks releasable stores of vWF. \u00a0\u00a0Type 2b should never be given DDAVP, as it is contraindicated due to its potential thrombogenicity. [17]", "contents": "Bleeding Disorders -- Treatment / Management. The treatment of von Willebrand disease consists of desmopressin (DDAVP) or cryoprecipitate.\u00a0 DDAVP will enhance the release of vWF in patients with Type 1 von Willebrand disease. \u00a0DDAVP is a synthetic derivative of antidiuretic hormone that acts on type 2 vasopressin receptors.\u00a0 It works by stimulating the release of vWF from endothelial cells by way of signaling through the cyclic adenosine monophosphate pathway which prompts the release of Weibel-Palade bodies into the endothelial cells and eventually into the plasma. [15] Additionally, DDAVP works on the renal collecting duct as an anti-diuretic.\u00a0 It reduces the amount of water that is eliminated in the urine potentially causing dilutional hyponatremia; therefore, patients should have fluid restriction maintained while receiving this medication. [16] DDAVP administered intravenously (0.3mcg/kg) will increase plasma Factor VIII and VWF levels by 3 to 5 times their baseline within 30 to 60 minutes after administration.\u00a0 DDAVP can also be administered subcutaneously (0.3 mcg/kg) or at fixed intranasal doses which is convenient for prophylactic treatment at home.\u00a0 DDAVP administration is expected to raise levels to 30 to 50% in patients with a baseline of 10% factor activity which may be sufficient for low-risk procedures but may require further supplementation to increase vWF to adequate levels needed for trauma or major surgery.\u00a0 Patients with a baseline of 20% factor level receiving DDAVP can see levels rise to 60 to 100% which would be suitable for most surgical procedures.\u00a0Approximately 10% of patients within the Type 1 category may fail to respond to DDAVP; therefore, the recommendation is that patients undergo a trial of DDAVP administration at diagnosis or before its clinical need.\u00a0 Patients with Type 2 and 3 von Willebrand disease typically require replacement products consisting of Factor VIII and vWF. It is also important to note that patients with Type 2a and 3 will not respond to DDAVP as the former possesses dysfunctional vWF and Type 3 lacks releasable stores of vWF. \u00a0\u00a0Type 2b should never be given DDAVP, as it is contraindicated due to its potential thrombogenicity. [17]"}
{"id": "article-18367_15", "title": "Bleeding Disorders -- Treatment / Management -- Replacement Products", "content": "There is a human plasma-derived concentrate of Factor VIII with an even higher concentration of vWF.\u00a0 This product has been the subject of extensive study and deemed to be the safest option for factor replacement as it has undergone a pasteurization process to inactivate any blood-borne viruses. \u00a0It has approval from the Food and Drug Administration (FDA) for the treatment and prevention of bleeding disorders in adult patients with Hemophilia A, as well as adult and pediatric patients with von Willebrand disease. [18]", "contents": "Bleeding Disorders -- Treatment / Management -- Replacement Products. There is a human plasma-derived concentrate of Factor VIII with an even higher concentration of vWF.\u00a0 This product has been the subject of extensive study and deemed to be the safest option for factor replacement as it has undergone a pasteurization process to inactivate any blood-borne viruses. \u00a0It has approval from the Food and Drug Administration (FDA) for the treatment and prevention of bleeding disorders in adult patients with Hemophilia A, as well as adult and pediatric patients with von Willebrand disease. [18]"}
{"id": "article-18367_16", "title": "Bleeding Disorders -- Treatment / Management", "content": "Factor VIII replacement with human plasma-derived concentrate of Factor VIII requires a simple weight-based calculation.\u00a0 The patient\u2019s weight (in kg) is multiplied by the desired percent level of Factor VIII, assuming that starting levels are 0.\u00a0That number then gets multiplied by the volume of distribution, which is approximately 0.5. [19] Thus, the dose of human plasma-derived concentrate of Factor VIII = weight in kg x desired Factor VIII level x 0.5. \u00a0For a 60kg female, with a target goal of 50% Factor VIII level: \u00a060 x 50 x 0.5 = 1500 units of Factor VIII.", "contents": "Bleeding Disorders -- Treatment / Management. Factor VIII replacement with human plasma-derived concentrate of Factor VIII requires a simple weight-based calculation.\u00a0 The patient\u2019s weight (in kg) is multiplied by the desired percent level of Factor VIII, assuming that starting levels are 0.\u00a0That number then gets multiplied by the volume of distribution, which is approximately 0.5. [19] Thus, the dose of human plasma-derived concentrate of Factor VIII = weight in kg x desired Factor VIII level x 0.5. \u00a0For a 60kg female, with a target goal of 50% Factor VIII level: \u00a060 x 50 x 0.5 = 1500 units of Factor VIII."}
{"id": "article-18367_17", "title": "Bleeding Disorders -- Treatment / Management", "content": "Alphanate is another commercially available, virally inactivated product with Factor VIII and ristocetin cofactor activity essential for vWF support. \u00a0The FDA has approved its use for both adults and children with Hemophilia A or von Willebrand disease who require treatment or prevention of spontaneous or trauma-related bleeding, including surgery. Factor IX concentrate is a commercially available product and has been subject to various purification techniques to eliminate the risk of viral transmission during its administration.\u00a0 These products have FDA approval for use in the setting of prevention and control of bleeding in patients with a factor IX deficiency. [20] .\u00a0Dosing of Factor IX concentrate = weight in kg x desired factor level x volume of distribution (which is 1 for Factor IX). \u00a0For a 60kg female with a target goal of 100% Factor IX level: 60 \u00a0x 100 x 1 = 6000 units.", "contents": "Bleeding Disorders -- Treatment / Management. Alphanate is another commercially available, virally inactivated product with Factor VIII and ristocetin cofactor activity essential for vWF support. \u00a0The FDA has approved its use for both adults and children with Hemophilia A or von Willebrand disease who require treatment or prevention of spontaneous or trauma-related bleeding, including surgery. Factor IX concentrate is a commercially available product and has been subject to various purification techniques to eliminate the risk of viral transmission during its administration.\u00a0 These products have FDA approval for use in the setting of prevention and control of bleeding in patients with a factor IX deficiency. [20] .\u00a0Dosing of Factor IX concentrate = weight in kg x desired factor level x volume of distribution (which is 1 for Factor IX). \u00a0For a 60kg female with a target goal of 100% Factor IX level: 60 \u00a0x 100 x 1 = 6000 units."}
{"id": "article-18367_18", "title": "Bleeding Disorders -- Treatment / Management -- Allogenic Replacement Therapy", "content": "Fresh frozen plasma (FFP) contains Factor VIII and vWF, but large volumes are needed to obtain adequate factor levels (20 to 25mL/kg). Cryoprecipitate is a human plasma-derived product containing high levels of Factor VIII, vWF and fibrinogen (Factor I). \u00a0It comes packaged in small volumes, so multiple bags are often required to obtain the adequate level of the factor desired. \u00a0\u00a0Virus inactivation is not routinely applied to these products therefore virally inactivated replacement products are considered a safer alternative to FFP and cryoprecipitate. \u00a0The absence of factor IX in cryoprecipitate negates its use in Hemophilia B. Platelet transfusions are necessary when bleeding continues despite normal Factor VIII levels. \u00a0Platelets can transport and localize the vWF from the site of the vascular injury.", "contents": "Bleeding Disorders -- Treatment / Management -- Allogenic Replacement Therapy. Fresh frozen plasma (FFP) contains Factor VIII and vWF, but large volumes are needed to obtain adequate factor levels (20 to 25mL/kg). Cryoprecipitate is a human plasma-derived product containing high levels of Factor VIII, vWF and fibrinogen (Factor I). \u00a0It comes packaged in small volumes, so multiple bags are often required to obtain the adequate level of the factor desired. \u00a0\u00a0Virus inactivation is not routinely applied to these products therefore virally inactivated replacement products are considered a safer alternative to FFP and cryoprecipitate. \u00a0The absence of factor IX in cryoprecipitate negates its use in Hemophilia B. Platelet transfusions are necessary when bleeding continues despite normal Factor VIII levels. \u00a0Platelets can transport and localize the vWF from the site of the vascular injury."}
{"id": "article-18367_19", "title": "Bleeding Disorders -- Treatment / Management -- Antifibrinolytic Acid Therapy", "content": "Aminocaproic acid is a synthetic analog of lysine used to control or prevent hemorrhage.\u00a0 It competitively reduces the conversion of plasminogen to plasmin thereby inhibiting fibrinolysis and promoting clot formation.\u00a0 It is typically administered as an intravenous infusion during a surgical procedure but is also available in an oral form for home use in patients with bleeding disorders. \u00a0It is available as a mouthwash or a tablet for oral bleeding, recurrent epistaxis or menorrhagia.\u00a0 This agent is FDA approved in the treatment of patients with bleeding disorders and is often useful as an adjunct therapy in patients with coagulopathic potential.", "contents": "Bleeding Disorders -- Treatment / Management -- Antifibrinolytic Acid Therapy. Aminocaproic acid is a synthetic analog of lysine used to control or prevent hemorrhage.\u00a0 It competitively reduces the conversion of plasminogen to plasmin thereby inhibiting fibrinolysis and promoting clot formation.\u00a0 It is typically administered as an intravenous infusion during a surgical procedure but is also available in an oral form for home use in patients with bleeding disorders. \u00a0It is available as a mouthwash or a tablet for oral bleeding, recurrent epistaxis or menorrhagia.\u00a0 This agent is FDA approved in the treatment of patients with bleeding disorders and is often useful as an adjunct therapy in patients with coagulopathic potential."}
{"id": "article-18367_20", "title": "Bleeding Disorders -- Treatment / Management -- Antifibrinolytic Acid Therapy", "content": "Tranexamic acid is a synthetic medication made from lysine which acts by competitively inhibiting plasminogen activation and is considered more potent than aminocaproic acid.\u00a0 At higher concentrations, it can act as a non-competitive inhibitor of plasmin.\u00a0 It has ten times the potency of aminocaproic acid and is FDA approved for use in patients with bleeding disorders. \u00a0It is available in intravenous and oral formulations. \u00a0The oral preparation can also help in the treatment of recurrent minor bleeding issues that occur at home and in preparation for dental work. [21]", "contents": "Bleeding Disorders -- Treatment / Management -- Antifibrinolytic Acid Therapy. Tranexamic acid is a synthetic medication made from lysine which acts by competitively inhibiting plasminogen activation and is considered more potent than aminocaproic acid.\u00a0 At higher concentrations, it can act as a non-competitive inhibitor of plasmin.\u00a0 It has ten times the potency of aminocaproic acid and is FDA approved for use in patients with bleeding disorders. \u00a0It is available in intravenous and oral formulations. \u00a0The oral preparation can also help in the treatment of recurrent minor bleeding issues that occur at home and in preparation for dental work. [21]"}
{"id": "article-18367_21", "title": "Bleeding Disorders -- Treatment / Management -- Hormonal Treatments", "content": "Oral contraceptives such as oral progestins and depot medroxyprogesterone have been shown to be effective in women with Type 1 von Willebrand disease with menorrhagia by significantly elevating circulating vWF levels.\u00a0 While the exact mechanism of estrogens influence on vWF is not entirely understood, it is hypothesized to occur as a result of its lipophilic nature, allowing it to penetrate the cytoplasm of the nuclear receptors thereby increasing gene transcription of the various clotting proteins. [22]", "contents": "Bleeding Disorders -- Treatment / Management -- Hormonal Treatments. Oral contraceptives such as oral progestins and depot medroxyprogesterone have been shown to be effective in women with Type 1 von Willebrand disease with menorrhagia by significantly elevating circulating vWF levels.\u00a0 While the exact mechanism of estrogens influence on vWF is not entirely understood, it is hypothesized to occur as a result of its lipophilic nature, allowing it to penetrate the cytoplasm of the nuclear receptors thereby increasing gene transcription of the various clotting proteins. [22]"}
{"id": "article-18367_22", "title": "Bleeding Disorders -- Differential Diagnosis", "content": "Malignancy Severe liver failure Thrombocytopenia Vitamin K deficiency Antithrombin III deficiency Massive transfusion Disseminated intravascular coagulation Lupus anticoagulant Protein C deficiency Protein S deficiency Idiopathic thrombocytopenic purpura (ITP) Medication side effects", "contents": "Bleeding Disorders -- Differential Diagnosis. Malignancy Severe liver failure Thrombocytopenia Vitamin K deficiency Antithrombin III deficiency Massive transfusion Disseminated intravascular coagulation Lupus anticoagulant Protein C deficiency Protein S deficiency Idiopathic thrombocytopenic purpura (ITP) Medication side effects"}
{"id": "article-18367_23", "title": "Bleeding Disorders -- Prognosis", "content": "Patients living with congenital bleeding disorders can expect to live full, productive lives with appropriate medical treatment, education and a management plan in case of trauma or surgery. \u00a0\u00a0Patients should consider wearing a medical identification bracelet so that they can receive proper management in case\u00a0they are involved in significant trauma or are unable to communicate their medical history verbally.", "contents": "Bleeding Disorders -- Prognosis. Patients living with congenital bleeding disorders can expect to live full, productive lives with appropriate medical treatment, education and a management plan in case of trauma or surgery. \u00a0\u00a0Patients should consider wearing a medical identification bracelet so that they can receive proper management in case\u00a0they are involved in significant trauma or are unable to communicate their medical history verbally."}
{"id": "article-18367_24", "title": "Bleeding Disorders -- Enhancing Healthcare Team Outcomes", "content": "The World Bleeding Disorder Registry (WBDR) comprises a record of patients with bleeding disorders who receive care through the Hemophilia Treatment Centers throughout the world who have voluntarily allowed their identities and private healthcare information to be entered into a web-based platform. This global data collection aids the\u00a0advancement of understanding the disease through evidence-based advocacy initiatives. \u00a0The WBDR is the only global registry of people with bleeding disorders around the world.\u00a0The accessibility of the information collected in this database strengthens the ability to diagnose and treat people with hemophilia. [23] Hematology nurses, internists, and hematologists should be familiar with the WBDR as it provides access to patient data online.", "contents": "Bleeding Disorders -- Enhancing Healthcare Team Outcomes. The World Bleeding Disorder Registry (WBDR) comprises a record of patients with bleeding disorders who receive care through the Hemophilia Treatment Centers throughout the world who have voluntarily allowed their identities and private healthcare information to be entered into a web-based platform. This global data collection aids the\u00a0advancement of understanding the disease through evidence-based advocacy initiatives. \u00a0The WBDR is the only global registry of people with bleeding disorders around the world.\u00a0The accessibility of the information collected in this database strengthens the ability to diagnose and treat people with hemophilia. [23] Hematology nurses, internists, and hematologists should be familiar with the WBDR as it provides access to patient data online."}
{"id": "article-18367_25", "title": "Bleeding Disorders -- Enhancing Healthcare Team Outcomes", "content": "The management and treatment of bleeding disorders require the collaborative efforts of an interprofessional health team that includes physicians, specialists, specialty-trained nurses, and pharmacists, all working and communicating across disciplines to bring about the most effective treatment and outcomes. [Level V]", "contents": "Bleeding Disorders -- Enhancing Healthcare Team Outcomes. The management and treatment of bleeding disorders require the collaborative efforts of an interprofessional health team that includes physicians, specialists, specialty-trained nurses, and pharmacists, all working and communicating across disciplines to bring about the most effective treatment and outcomes. [Level V]"}
{"id": "article-18367_26", "title": "Bleeding Disorders -- Review Questions", "content": "Access free multiple choice questions on this topic. Comment on this article.", "contents": "Bleeding Disorders -- Review Questions. Access free multiple choice questions on this topic. Comment on this article."}